Potassium Deficiency during Treatment
with Brinaldix K SIR,-We wish to report four cases of severe potassium deficiency seen recently in this hospital in patients receiving Brinaldix K. Case 1.-A 48-year-old woman was admitted to hospital with weakness, depression, and lassitude. For four months she had been known to be hypertensive, with an impaired creatinine clearance (12 ml/min), and had recently developed cardiac asthma. In addition to clonidine 0.1 mg four times daily for her hypertension she had been receiving digoxin 0-25 mg daily and Brinaldix K two tablets daily for three weeks. Severe hypokalaemia was found (see table) and treated by withdrawal of Brinaldix K and addition of Sando-K, with return to normal values over the following three days. In spite of the impaired renal function and hypokalaemia, no electrocardiographic features of digitalis toxicity were found.
Case 2.-A 69-year-old woman known to be hypertensive for six months was admitted to hospital with extreme weakness, nausea, and postural hypotension. Her hypertension was at the time being treated with clonidine 0.1 mg twice daily. She had been taking digoxin 0.25 mg daily for several months, and on admission showed gross electrocardiographic evidence of digitalis toxicity, with coupling and ST-segment depression. Electrolyte estimations confirmed marked hypokalaemia. For one month prior to admission she had been receiving Brinaldix K one tablet daily. This was discontinued after admission, and potassium supplements added, with return of serum potassium values to normal levels in seven days and disappearance of digitalis intoxication in three days.
Case 3.-A 79-year-old woman was admitted to hospital having been found on her kitchen floor, where she had presumably been for some hours. We would remind them of almost completely contrary evidence' presented in a symposium report from which they quote two references. This other study involved obese patients-to whom fenfluramine is commonly administered. The dose was 40 mg orally four times daily for one week before repeating the exercise study. Plasma growth hormone concentrations showed striking increments with exercise, and these were even greater on the drug-"the differences between the mean values . . . when fenfluramine was added were statistically significant at 1A, 22, and 41 hours after the start of the period of exercise." Again contrary to Mr. Sulaimain's and Dr. Johnsons' findings, changes in blood glucose and the plasma concentration of insulin were not found during periods of exercise more prolonged than those they used.
Furthermore, the most vigorous and consistent secretion of growth hormone occurs during natural sleep. Having previously mentioned that chronic intake of fenfluramine, far from suppressing growth hormone secretion during sleep, may lead to increased plasma levels,2 we now show in the accompanying figure an example where plasma levels (in ng/ml) were consistently higher throughout a night, in the case of a man who had received oral fenfluramine for over two months, than was the case six weeks later when he had been off fenfluramine for a month. Blood was withdrawn without disturbing sleep, using a venous catheter technique. Time of niqht
In studying the mode of action of a drug such as fenfluramine it would seem important that the conditions of administration should resem-ble as nearly as possilble those in which it is commonly used.-We are, etc.,
